London-based biotech company Engitix has raised €21 million ($25 million) in a Series A extension to advance its work on therapies targeting the extracellular matrix (ECM) in cancer and fibrotic diseases.
Your go-to source for the latest Startup developments.
Would you like us to send you the latest news from the startup world?